Menu PATIENTS AND CAREGIVERS We want to do our part to keep cancer from disrupting lives – not only by developing targeted cancer therapies, but also by providing access to educational resources that help patients and caregivers on their journey to more good days. OUR CLINICAL TRIALS We have a variety of ongoing clinical trials in different therapeutic areas, which are detailed below. If you have any questions about any of these trials, contact our Medical Affairs team via email medicalaffairs@immunogen.com or by phone (+1-781-895-0115). ACUTE MYELOID LEUKEMIA (AML) ClinicalTrials.gov Identifier: NCT03386513 Description: Phase 1, Multi-center, Open-label Study of IMGN632 in Patients With Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies Status: Recruiting BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) ClinicalTrials.gov Identifier: NCT03386513 Description: Phase 1, Multi-center, Open-label Study of IMGN632 in Patients With Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies Status: Recruiting OVARIAN CANCER ClinicalTrials.gov Identifier: NCT04296890 Description: SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Status: Recruiting ClinicalTrials.gov Identifier: NCT04209855 Description: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Status: Recruiting UNDERSTANDING ADCs The concept of an ADC is simple: select a cancer-killing toxin and attach it to a specific antibody using a biodegradable linker. But, what we learned from 40 years of research with hundreds of patients and caregivers was that, while “simple” for scientists, ADCs aren’t necessarily easy to understand for non-scientists. With this insight in mind, we created a simple animation that explains ADCs and how they work. CAREGIVER RESOURCES Visit the National Patient Advocate Foundation to learn more about person-centered care Find out what to expect if you become a caregiver for a person with cancer from the American Cancer Society Learn more about the services, programs, and resources the Family Caregiver Alliance provides for caregivers HEMATOLOGIC DISORDERS Explore acute myeloid leukemia (AML) from the Leukemia and Lymphoma Society Explore blastic plasmacytoid dendritic cell neoplasm (BPDCN) from the Leukemia and Lymphoma Society Get to know the Leukemia and Lymphoma Society and the resources they provide IMMUNOGEN RESOURCES Learn more about our Expanded Access Policy Contact our Medical Affairs Team CLINICAL TRIAL RESOURCES Visit MedlinePlus.gov to understand how Medical Research works Learn more about clinical studies on ClinicalTrials.gov Access clear and simple clinical trial information designed for patients and caregivers at Cancer.gov OVARIAN CANCER Watch a video about ovarian cancer information from the National Cancer Institute Access a variety of easy-to-understand ovarian cancer resources from the National Ovarian Cancer Coalition Learn more about the largest global organization dedicated to fighting ovarian cancer, the Ovarian Cancer Research Fund Alliance See how the Clearity Foundation is working to improve treatment options for ovarian cancer patients Connect to ovarian cancer support programs through Sharsheret Support World Ovarian Cancer Day through the World Ovarian Cancer Coalition CONTACT US PRIVACY POLICY USAGE POLICY © 2021 ImmunoGen, Inc., All Rights Reserved ImmunoGen, the ImmunoGen logos, and TARGET A BETTER NOW are trademarks or registered trademarks of ImmunoGen, Inc.